AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie generated FY2025 revenue of $61.2B, up 8.6%, and is projected to reach $67.2B in 2026, while net income is expected to rise sharply from $4.2B to $14.6B, supported by Skyrizi, Rinvoq and its Apogee Therapeutics acquisition. Bristol Myers Squibb posted $48.2B of FY2025 revenue, down 0.2%, but delivered a higher 14.6% net margin and trades at 8.9x forward P/E versus AbbVie's 18.6x. The article favors AbbVie for its stronger growth outlook despite concentration, patent-expiry and pricing risks; BMY is viewed as inexpensive but facing an uncertain recovery amid litigation, debt and blockbuster drug erosion.

Analysis

The relevant divergence is not headline growth versus value, but earnings-quality durability. ABBV’s premium assumes Skyrizi/Rinvoq can offset multiple simultaneous pricing and lifecycle headwinds; with immunology now the central profit pool, any deceleration in new-patient starts, payer access, or net-price realization would have an outsized effect on both estimates and its 18.6x forward multiple. The acquisition of APGE adds optionality but should be treated as pipeline-duration insurance rather than near-term EPS support until clinical differentiation, deal consideration, and commercialization timing are independently confirmed.

BMY’s apparent valuation discount is better viewed as a patent-cliff/litigation reserve than a simple rerating opportunity. A low multiple can persist while investors lack confidence that new-launch growth can replace erosion from mature franchises; the key catalyst over the next 1-3 quarters is not a modest revenue rebound but evidence that growth-brand sales are exceeding the embedded replacement curve. BMY’s higher accounting margin and liquidity cushion offer more downside protection than the equity narrative implies, but legal outcomes and oncology competitive losses create discontinuous downside that a static P/E does not capture.

Second-order beneficiaries of branded-drug volume growth are MCK, COR, and CAH, though distributor economics are driven more by mix, working capital, and contract terms than manufacturer list-price growth. ABBV’s concentration through these channels makes gross-to-net trends and inventory days more informative than reported prescription demand; any channel inventory normalization could create a temporary revenue miss without signaling a demand collapse. In oncology, MRK is the cleaner relative beneficiary if BMY’s Opdivo competitive position weakens, while CYTK remains an event-driven litigation/clinical-risk name rather than a direct BMY hedge.

Consensus likely overweights ABBV’s reported earnings inflection and underweights the probability that payer pressure converts growth into lower net pricing. Conversely, BMY may be under-owned enough that a credible pipeline or growth-brand beat can drive a sharp multiple response, but this requires an identifiable estimate-revision catalyst rather than valuation alone. This is a relative-quality trade, not a broad pharma beta call.

Key Decisions for Investors

• Initiate a 3-6 month long ABBV / short BMY pair only on relative weakness that widens BMY’s discount further: ABBV has superior near-term estimate momentum, while BMY needs proof before rerating. Target 10-15% relative return; exit if ABBV immunology guidance is cut or BMY growth-brand sales drive upward FY estimates.
• For ABBV exposure, prefer a staged cash-equity entry around quarterly prescription and gross-to-net disclosure rather than chasing pre-earnings momentum. Thesis is falsified by sustained Skyrizi/Rinvoq growth deceleration or a payer-driven reduction in 2027 net-sales outlook; these would threaten both EPS and premium-multiple support.
• Maintain BMY as a watch-list value catalyst candidate, not a standalone long, until management demonstrates that growth-brand performance offsets mature-product erosion for two consecutive quarters. A favorable litigation development or upward revenue guidance revision could justify covering the BMY leg of the pair rapidly; adverse legal reserve expansion is the primary downside trigger.
• Use MCK or COR as lower-volatility ancillary exposure to branded specialty-pharma volumes, but do not position on ABBV growth alone. Monitor distributor receivable/inventory trends and manufacturer service-fee commentary; deterioration would signal channel stress and can precede pharma revenue volatility.